Skip to main content

Table 3 Summary of recurrently mutated genes in only resistant or sensitive cases by whole-exome sequencing

From: Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma

Gene Symbol

Case 1 (R)

Case 2 (R)

Case 3 (R)

Case 4 (S)

Case 5 (S)

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Genes mutated in > 1 platinum-resistant cases only (16)

 *ADGRV1/GPR98a

 

X

 

X

      

 *AOC1/ABP1a

 

X

  

X

Xe

    

 ARHGAP5

  

X

  

Xe

    

 *CSPG4a

X

 

X

X

      

 KIR2DL1

 

X

  

X

     

 KRTAP4-11

X

    

Xe

    

 MMP9

 

X

X

       

 *MTMR11c

 

X

  

X

Xd

    

 MUC17c

 

X

   

Xe

    

 MUC20c

 

X

   

Xe

    

 *OR52N5c

 

X

X

X

      

 PAK2c

   

X

 

Xe

    

 *PCDHB11c

  

X

X

 

Xe

    

 *TMEM14Bc

 

X

X

X

      

 TTN

 

X

X

       

 USP8

 

X

X

       

Genes mutated in > 1 platinum-sensitive cases only (5)

 *CYP2D6b

      

X

 

X

 

 *DNAH5b

      

X

X

X

 

 FAM186A

       

X

X

 

 MACF1

       

X

X

 

 NUTM1b

      

X

 

X

 
  1. Genes that were recurrently mutated in either resistant or sensitive cases (irrespective of time point) are shown. Whether a non-synonymous exonic mutation was detected in pre-NACT and/or post-NACT samples from each case is indicated by an “X”. Specific mutations are included in Additional File 3. *included on targeted panel; agene mutated in pre-NACT samples from > 1 resistant cases but not sensitive cases (CSPG4); bgene mutated in pre-NACT samples from both sensitive cases but not resistant cases (CYP2D6, NUTM1, DNAH5); cgene mutated in post-NACT samples from > 1 resistant cases but not sensitive cases (ADGRV1, AOC1, MTMR11, MUC17, MUC20, OR52N5, PAK2, PCDHB11, TMEM14B); dgene mutated in both omental and ovarian post-NACT samples from Case 3 (MTMR11); egene mutated in only 1 post-NACT sample from Case 3 (AOC1, ARHGAP5, KRTAP4-11, MUC17, MUC20, PAK2, PCDHB11)